Kisspeptin-10 research: define the fragment before the assay.

“Kisspeptin” does not identify one test material

The IUPHAR nomenclature review describes kisspeptin-54 as a C-terminally amidated 54-amino-acid peptide and identifies KP-14, KP-13 and KP-10 as shorter C-terminal fragments.[1] PubChem records Kisspeptin-10 separately as CID 25240297 with molecular formula C63H83N17O14.[2] These references help define the analyte; they do not authenticate a seller lot, counterion, quantity basis, purity, stability or experimental performance.

Match the fragment to the research question

The nomenclature review calls KP-10 the smallest active C-terminal fragment and reports that kisspeptin-receptor activation couples to Gq/11, phospholipase C and calcium mobilization.[1] That family-level summary does not make KP-10, KP-54, analogs or differently terminated materials interchangeable. Record fragment length, sequence, terminal chemistry, salt or counterion and quantity basis when those facts are supplied.

Receptor activation and binding are different measurements

A 2001 receptor-deorphanization study expressed human AXOR12 in mammalian cells and reported high-potency agonism for KiSS-1-derived peptides with a shared C-terminal amidated motif.[3] This is engineered-cell functional evidence. It is not a direct lot test, a comprehensive selectivity panel or proof that every product labeled “kisspeptin” has equivalent activity.

Trafficking can change the calcium readout

A 2014 study used Chinese hamster ovary and GT1-7 cells expressing KISS1R. It reported a biphasic intracellular-calcium response and experiments implicating receptor internalization and recycling in the sustained phase.[4] This matters for assay design: exposure time, washout, receptor expression, trafficking inhibitors and the chosen analysis window may change the observed signal.

Analog studies should not be assigned to KP-10

A 2010 structure-modification study compared KP-10 analogs using KISS1R binding, ERK1/2 phosphorylation and mouse experiments.[5] One modified analog differed from KP-10 in receptor affinity and organism-level observations. The study demonstrates why an analog name, sequence change or stereochemical change must be recorded explicitly rather than folded into a generic “kisspeptin” evidence claim.

Genetic evidence defines receptor biology, not reagent performance

A 2003 study investigated GPR54 variants using human genetics, transfected COS-7-cell inositol-phosphate experiments and a knockout-mouse model.[6] Those evidence layers support the biological importance of the receptor pathway, but they do not establish the identity, quality, purity, stability or suitability of a commercial KP-10 material.

Procurement and assay checks for kisspeptin-10

• Confirm that the requested material is KP-10 rather than KP-54, KP-14, KP-13 or an analog.
• Record the supplied sequence, C-terminal amidation, stereochemistry, salt or counterion, quantity basis and formulation.
• Match current lot documentation to the exact listing and received lot; database and literature records are not lot evidence.
• Define the receptor species and construct, cell background, expression system, endpoint, exposure window, controls and acceptance criteria.
• Distinguish binding, calcium mobilization, ERK phosphorylation, receptor trafficking and organism-level endpoints in the study record.
• Verify current seller price, availability, shipment eligibility and institutional receiving requirements before ordering.

Review the current research format

The card below uses current seller-catalog title, format, price and availability facts retrieved during generation. The literature above does not establish the identity, quality, purity, stability, performance or results of the seller product.